

Company name : KYORIN Holdings, Inc.  
Representative Director, President : Minoru Hogawa  
Securities Code : 4569, TSE 1st Sec.

**Release of KIPRES<sup>®</sup> OD Tablets 10mg,  
a treatment for bronchial asthma and allergic rhinitis**

TOKYO, Japan (December 11, 2015) — Kyorin Pharmaceutical Co., Ltd. (“Kyorin”) (Head office: Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc., released today a leukotriene receptor antagonist / bronchial asthma and allergic rhinitis treatment drug of “KIPRES<sup>®</sup> OD Tablets 10mg” (INN: montelukast sodium). The product received marketing authorization from the Ministry of Health, Labour and Welfare (“MHLW”) in August this year.

The leukotriene receptor antagonist is selective for the Cys LT<sub>1</sub> receptors developed by Merck & Co., Inc. (Kenilworth, N.J., U.S.A.). Kipres<sup>®</sup> OD Tablets (10 mg) are designed to quickly disintegrate in the mouth, the orally disintegrating tablets can be taken without water and are easily ingested orally by the elderly and patients who have grown less capable of swallowing conventional solid formulations. We believe the tablets offer proper and desirable choices of dosage forms to more patients, and will lead to improvements in medication compliance.

Moving forward, Kyorin Pharmaceutical will continue supporting the treatment of bronchial asthma and allergic rhinitis with the addition of Kipres<sup>®</sup> OD Tablets (10 mg) to its existing lineup of dosage forms.

The sales of the drug is factored in consolidated forecast for the fiscal year ending March 31 2016.

< Product information >

1.Brand name : KIPRES<sup>®</sup> OD Tablets 10mg

2. Active ingredient : Montelukast Sodium

3. Indications : Bronchial Asthma, Allergic Rhinitis

4. Dosage and Administration :

< Bronchial Asthma > Recommended dosage for adults is usually 10mg as montelukast orally administered once daily before bedtime.

< Allergic Rhinitis > Recommended dosage for adults is usually 5-10mg as montelukast orally administered once daily before bedtime.

5. NHI Price : ¥222.00

< Product photo >

